Resources from the same session
Welcome and introduction
Presenter: Wolfgang Janni
Session: Novartis - Breaking new ground with CDK4/6 inhibitors: Case-based discussions on treatment decisions in HR+/HER2- breast cancer
Resources:
Webcast
Unmet need in HR+/HER2- early breast cancer
Presenter: Wolfgang Janni
Session: Novartis - Breaking new ground with CDK4/6 inhibitors: Case-based discussions on treatment decisions in HR+/HER2- breast cancer
Resources:
Webcast
Exploring CDK4/6 inhibitor clinical data in HR+/HER2- early breast cancer
Presenter: Carlos Barrios
Session: Novartis - Breaking new ground with CDK4/6 inhibitors: Case-based discussions on treatment decisions in HR+/HER2- breast cancer
Resources:
Webcast
Reviewing the treatment landscape for HR+/HER2- advanced breast cancer
Presenter: Wolfgang Janni
Session: Novartis - Breaking new ground with CDK4/6 inhibitors: Case-based discussions on treatment decisions in HR+/HER2- breast cancer
Resources:
Webcast
Closing and key takeaways
Presenter: Wolfgang Janni
Session: Novartis - Breaking new ground with CDK4/6 inhibitors: Case-based discussions on treatment decisions in HR+/HER2- breast cancer
Resources:
Webcast